Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
completion around
Principal Investigator
by Siddharth Singh, MD
Headshot of Siddharth Singh
Siddharth Singh

Description

Summary

The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.

Details

Keywords

Ulcerative Colitis, Crohn Disease, Pragmatic

Eligibility

Locations

  • UC San Diego Health accepting new patients
    La Jolla California 92037 United States
  • Hoag Hospital accepting new patients
    Irvine California 92618 United States

Lead Scientist at UCSD

  • Siddharth Singh, MD
    Associate Professor Of Clinical, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 156 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT05230173
Study Type
Interventional
Participants
Expecting 250 study participants
Last Updated